Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities

12/23/2014 05:25 PM EST

Hospira, Inc. (NYSE: HSP), announced today it has initiated a voluntary recall of 10 lots, identified below, of MitoXANTRONE (both human and veterinary), due to confirmed subpotency and elevated impurity levels.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420